To Construct a Prognosis Prediction Model for ECMO Patients Based on Machine Learning Algorithms
Launched by ZHUJIANG HOSPITAL · Oct 22, 2024
Trial Information
Current as of June 09, 2025
Completed
Keywords
ClinConnect Summary
Extracorporeal Membrane Oxygenation (ECMO) is used to provide continuous extracorporeal respiratory and circulatory support for patients with severe cardiopulmonary failure. It is the most important life support method in critical care medicine, and also one of the most complex and expensive treatment methods in intensive care unit (ICU). It takes a lot of resources to maintain. Therefore, it is particularly important to strictly grasp the indications of patients and accurately predict the prognosis of patients to assist clinical decision-making.
Several previous published studies have use...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All patients who underwent ECMO in our hospital and were registered in the CSECLS registry database (ClinicalTrials.gov Identifier:NCT04158479) from January 1, 2018 to now were retrospectively collected.
- Exclusion Criteria:
- • ECMO was discontinued for non-medical reasons.
- • Under 18 years of age.
About Zhujiang Hospital
Zhujiang Hospital, affiliated with the Southern Medical University in Guangzhou, China, is a leading clinical research institution dedicated to advancing medical science and improving patient care through rigorous clinical trials. With a strong commitment to ethical standards and patient safety, the hospital boasts a multidisciplinary team of experienced researchers and healthcare professionals. Its state-of-the-art facilities enable the execution of innovative studies across various therapeutic areas, contributing valuable insights to the global medical community. Zhujiang Hospital aims to foster collaboration with academic institutions, pharmaceutical companies, and regulatory bodies to ensure the successful development of new therapies and enhance treatment options for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guangdong, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported